GlassScriptPhysician profile
Laura Gaudette
NPI 1336635580
$1,904.94
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,209 · 2022: $345 · 2023: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $256 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $255.89 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $411.34 | 2021-2023 | |
| Novo Nordisk INC | $169.49 | 2021-2022 | |
| Lilly USA, LLC | $138.51 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $119.70 | 2023 | Sotyktu |
| Pfizer INC. | $102.07 | 2021-2022 | |
| Janssen Biotech, INC. | $94.99 | 2023 | Tremfya, Stelara |
| Astrazeneca Pharmaceuticals LP | $93.32 | 2021-2022 | |
| Glaxosmithkline, LLC. | $77.80 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $73.45 | 2021 | |
| Amgen INC. | $71.28 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $65.16 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.16 | 2021 | |
| Esperion Therapeutics, INC. | $63.45 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.64 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $45.16 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.97 | 2021 | |
| Dexcom, INC. | $40.88 | 2021-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $40.64 | 2021 | |
| Janssen Pharmaceuticals, INC | $26.96 | 2021-2022 | |
| Insmed, INC. | $20.51 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.02 | 2021 | |
| Nevro Corp. | $17.76 | 2021 | |
| Eisai INC. | $14.77 | 2022 | |
| Daiichi Sankyo INC. | $12.35 | 2021 | |
| Amarin Pharma, INC. | $12.27 | 2021 | |
| Astellas Pharma US INC | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Gaudette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.